Paul
04-05-2004, 10:29 AM
Colleen,
Click on the cross-link below and it will take you to an article entitled, "Gemcitabine (Gemzar) and trastuzumab (Herceptin) combinations for patients with metastatic breast cancer overexpressing HER2/neu." The summary provides as follows:
Stein S, DeMichele A, Domchek S, Fox K.
Abramson Cancer Center, University of Pennsylvania, Philadelphia 19104, USA. steven.stein@uphs.upenn.edu
In HER2/neu-positive metastatic breast cancer, the combination of chemotherapy and trastuzumab has become a standard of care. This review discusses HER2/neu overexpression in breast cancer and the use of trastuzumab-based therapies. Specifically, the rationale for a gemcitabine/trastuzumab combination in this disease entity and the available clinical data on the use of the combination are discussed. Response rates of 12%-42% have been seen with single-agent gemcitabine and 37%-62% with trastuzumab/gemcitabine combinations. Further work is currently ongoing to examine this promising combination.
The article appears in the January 2004 Supplement issue of the Clinical Breast Cancer Journal (Clin Breast Cancer. 2004 Jan;4 Suppl 3:S117-20.) I thought you may to obtain a copy of the article while evaluating your Gemzar clinical trial issue.
Warmest regards,
Paul
Click on the cross-link below and it will take you to an article entitled, "Gemcitabine (Gemzar) and trastuzumab (Herceptin) combinations for patients with metastatic breast cancer overexpressing HER2/neu." The summary provides as follows:
Stein S, DeMichele A, Domchek S, Fox K.
Abramson Cancer Center, University of Pennsylvania, Philadelphia 19104, USA. steven.stein@uphs.upenn.edu
In HER2/neu-positive metastatic breast cancer, the combination of chemotherapy and trastuzumab has become a standard of care. This review discusses HER2/neu overexpression in breast cancer and the use of trastuzumab-based therapies. Specifically, the rationale for a gemcitabine/trastuzumab combination in this disease entity and the available clinical data on the use of the combination are discussed. Response rates of 12%-42% have been seen with single-agent gemcitabine and 37%-62% with trastuzumab/gemcitabine combinations. Further work is currently ongoing to examine this promising combination.
The article appears in the January 2004 Supplement issue of the Clinical Breast Cancer Journal (Clin Breast Cancer. 2004 Jan;4 Suppl 3:S117-20.) I thought you may to obtain a copy of the article while evaluating your Gemzar clinical trial issue.
Warmest regards,
Paul